Hōʻike ʻia ʻo MHC Class I i ka Psoriatic Arthritis

Pane wikiwiki

Hoʻohālikelike i ka hōʻike peptide MHC Class I skewed i ka psoriatic arthritis me ka hoʻohana ʻana i nā paneli peptide maʻamau, Nā kūlana SIL, a me ka LC-MS/MS immunopeptidomics.

Ka Immunological Mechanism: Pehea ka hiki ʻana o Alleles i ka MHC Class I Ligandome

Ma ka pae mole, Hoʻopili ikaika ʻia ka psoriatic arthritis i nā alleles hiki ke hoʻopili ʻia i ka HLA Class I, ʻoi loa ka HLA-C06:02, HLA-B27, HLA-B13, a me HLA-B57. E noiʻi i ka peptide hoʻopaʻa haʻawina cleft polymorphism (2020) e hōʻike ana i ka maʻalahi o ka PsA e alakaʻi nui ʻia e nā hiʻohiʻona kaʻana like ma ka HLA peptide-binding groove—ʻo ia hoʻi kahi hiʻohiʻona ʻokoʻa o ka hoʻopiʻi maikaʻi ʻole i ka ʻeke B a me nā koena polymorphic ma ke kūlana. 97.

Hoʻololi maoli kēia hoʻolālā hale i ka makemake paʻa o ka mole MHC Class I. Ma mua o ka hōʻike ʻana i kahi ākea, homeostatic cross-section o ka proteome cellular, ʻO nā allotypes hiki ke hoʻonui i nā peptides ponoʻī i loaʻa nā koena kumu, e like me ka arginine ma ke kūlana 2 (P2) a i ʻole kūlana 3 (P3). Ke hui pū ʻia me nā ʻano like ʻole o ka antigen-processing aminopeptidases (ERAP1 a me ERAP2), e like me ka mea i hoikeia ma ka ʻO ka ʻae ʻana o EULAR ma ka MHC-I-opathies (2023), ʻO ka mīkini hana antigen-processing cell e hoʻopuka i kahi peptidome skewed.

Hōʻike ʻia ʻo MHC Class I i ka Psoriatic Arthritis

'ikamu

kikoʻī

Ka Hana Maʻamau

ʻOkoʻa Homeostatic Proteome → Unskewed HLA-I Ligandome → Immune Tolerance

Mokuaina ma'i PsA

Nā Allotypes HLA + Nā ʻano like ʻole ERAP → Skewed P2/P3 Arginine-Rich Ligandome → Autoreactive CD8+ T Cell Activation

Ma nā pūnaewele synovial a me nā pūnaewele entheseal, ʻO ka hopena o kēia hōʻike hōʻike i ka hōʻike nui ʻana o nā peptides autoantigenic kikoʻī - e like me nā ʻāpana i loaʻa mai nā protein pili melanocyte e like me ADAMTSL5 a i ʻole nā ​​​​protein matrix kikoʻī cartilage.. Hoʻopili kēia mau peptides ponoʻī i ka autoreactive CD8+ T, ka hoʻoulu ʻana i nā cascade inflammatory localized a me ka luku ʻana i nā ʻiʻo.

No nā mea noiʻi biopharma, ka helu ʻana i kēia mau hoʻololi hōʻike maʻalahi-e hoʻopili pinepine ana i nā loli liʻiliʻi liʻiliʻi i ka hōʻike peptide pae femtomole-he mea nui ia e hōʻoia inā hoʻihoʻi maikaʻi ka therapeutic moho i ke kaulike ligandome maʻamau a i ʻole ke kāpae ʻana i ka hōʻike peptide pathogenic..


No ke aha i hiki ʻole ai i ka Untargeted Discovery Proteomics ke helu i nā hoʻololi hōʻike

E ana i ka hoike HLA Papa I, ʻO ka noiʻi mua i hilinaʻi nui ʻia i ka loaʻa ʻana o ka Data-Dependent Acquisition (DDA) wai chromatography-tandem mass spectrometry (LC-MS/MS). ʻOiai he mea waiwai ʻo DDA no ka palapala ʻāina qualitative mua, hōʻike ia i nā palena koʻikoʻi ke hoʻohana ʻia i nā haʻawina unuhi nui:

  1. Ka Laʻana Stochastic a me nā kumukūʻai kiʻekiʻe e nalowale ana: Ma DDA, koho ka mass spectrometer i nā ion precursor ikaika loa no ka māhele ʻana i kēlā me kēia pōʻai hana.. No ka mea, ʻaʻole tryptic maoli nā peptides HLA Class I, loli nui ka loa (maʻamau 8 i 11 nā ʻakika amino), a aia ma kahi haʻahaʻa loa (nā femtomoles no ka milligram o ka ʻiʻo a i ʻole nā ​​kope no ke kelepona), Loaʻa pinepine ʻia nā peptides pathogenic haʻahaʻa ma waena o nā cohorts lapaʻau, e hāʻawi ana i nā kumukūʻai nalowale o 40% i 60%.

  2. Ka nele i nā heleuma nui loa: Hoʻopili maikaʻi ʻole ka ikaika kiʻekiʻe o DDA me nā helu kope o ka cell-surface. Me ka ʻole o nā kūlana isotopic i kūlike, hoʻololi ka ʻōlelo maʻalahi (e.g., he 2.5-fold ka piʻi ʻana o kahi peptide autoantigenic) ʻAʻole hiki ke hoʻokaʻawale ʻia mai ka matrix-induced ionization fluctuations a i ʻole nā ​​poho lawelawe ʻana i ka laʻana.

  3. Nā mea hana mai Substandard Custom Peptides: ʻO ka hōʻoia ʻana i nā hits immunopeptidomic pono nā kuhikuhi peptide synthetic. Eia naʻe, nā peptides synthetic maʻamau maʻamau maʻamau (70% i 80% ka maemae) lawe i nā haumia kemika nui. Ke koena trifluoroacetate (TFA) ʻO nā counter-ions ke kumu o ka ionization electrospray koʻikoʻi (ESI) kinai ana, ʻoiai ʻo ka hoʻopau ʻole ʻana o nā huahana e hana i nā hōʻailona precursor maikaʻi ʻole e hoʻololi i ka pololei quantitative..

Ki Takeaway: He mea kūpono nā proteomic DDA untargeted no ka ʻike mua ʻana i ka ligand, akā ʻo ka unuhi ʻana i ka manaʻo hōʻoia e koi i ka LC-MS/MS assays i hoʻopaʻa ʻia e nā peptides synthetic maʻemaʻe kiʻekiʻe a me nā kūlana isotopic kaumaha..


ʻO ka manaʻo koʻikoʻi: He Kawai Hana Immunopeptidomic Hoʻohui

No ka hoʻokō ʻana i ke koʻikoʻi analytical i koi ʻia no ka hōʻoia ʻana i ka pahuhopu IND, Ke neʻe nei nā hui noiʻi unuhi i nā ʻano LC-MS/MS i manaʻo ʻia—e like me Selected Reaction Monitoring (SRM), Ka nānā ʻana i ka hoʻohālikelike ʻana (PRM), a me PRM Kūloko Kūloko (IS-PRM). ʻO ka hoʻokō ʻana i kēia mau hoʻāʻo kiʻekiʻe e koi ana i kahi kumu hoʻohālike lawelawe ʻekolu kia hoʻohui.

Kia Kawai Hana

Mea ʻenehana

ʻO ke kuleana koʻikoʻi i ka Immunopeptidomics

Pills 1: Nā Panel Peptide Kuʻuna

Kiʻekiʻe-throughput, nā hale waihona puke peptide piha

Hāʻawi i nā kuhikuhi kukui synthetic e pili ana i nā ligand HLA i wānana a ʻike ʻia no ka calibration manawa paʻa a me ka hale waihona puke MS/MS spectral..

Pills 2: SIL Kaumaha Kaumaha

ʻO nā peptides i hoʻopaʻa ʻia i ka isotope paʻa e hoʻokomo ana i ^{13}C₆, ^{15}N₄ Arg a i ʻole ^{13}C₆, ^{15}N₂ Papa inoa

Lawelawe e like me ka pololei co-eluting heleuma kūloko, hiki i ke ana hoololi pili pili pono a me ka helu o ka ili-ili.

Hoʻohuihui Peptide Pills 3: Kākoʻo Hoʻomohala Assay

ʻO ka hoʻokaʻawale ʻana i ka pukaaniani hoʻomaʻamaʻa, net peptide maʻiʻo calibration, hoʻololi kūʻē-ion

Kāohi i ka hoʻopilikia nui isobaric, hoʻopau i ka hoʻopau ʻana i ka ion TFA, a e hōʻoia i ka hoʻopuka hou ʻana o ka hoʻāʻo ʻana i ka batch-to-batch.

1. ʻO nā Panel Peptide Kuʻuna

Hoʻomaka ka immunomics unuhi me nā paneli i hoʻopaʻa ʻia maʻamau e pili ana i ka peptidome pili i ka maʻi.. No ka noiʻi PsA, pono nā panela e uhi i ka HLA-C kiko'ī06:02 a me HLA-B27 nā kumu paʻa. Ke hoʻohana nei i kahi kahua kūikawā like Hoʻopili ʻia ʻo Peptide Synthesis hōʻoia e hana ʻia nā peptides synthetic me ka ʻoiaʻiʻo o ke kaʻina hana, nā mana lōʻihi koʻikoʻi, a me ka maemae kiekie (≥ 95%), ka hāʻawi ʻana i nā hale waihona puke kikoʻī kikoʻī no ka loaʻa ʻana o LC-MS/MS.

2. Paʻa Isotope–Labeled (SIL) Nā Kūlana Kūloko

No ka helu ʻana i ka hoʻololi ʻana o ka hōʻike, Hoʻokomo ʻia nā peptides kaumaha synthetic i loko o ka hoʻohālike HLA ligand immunopurified ma mua o ka nānā ʻana o LC-MS/MS.. Ma ka hoʻokomo ʻana i nā isotopes kaumaha paʻa (^{13}C a me ^{15}N) i loko o ka C-terminal koena kumu (e like me Heavy Arginine [+10 A] a i ʻole Lysine kaumaha [+8 A]), hōʻike ka maʻamau kaumaha i ka manawa paʻa chromatographic like, ionization pono, a me ka hana ʻāpana e like me ka ligand māmā endogenous.

E like me ka kikoʻī ma ka noiʻi ma i kuhikuhi ʻia i ka IS-PRM immunopeptidomic workflows (2024), leveraging ʻO nā Peptides i hoʻopaʻa ʻia i ka Isotope hiki i nā spectrometers nui ke hoʻoikaika i ka loaʻa ʻana o ka pahuhopu, hoʻopau i nā hopena matrix a hiki ke hoʻonui i ka helu ʻana i lalo i nā pae hoʻokahi-attomole.

3. Hoʻomohala ʻia ʻo Assay Development & Kākoʻo maikaʻi

ʻAʻole lawa nā kūlana SIL kiʻekiʻe wale nō inā e nānā ʻole ʻia nā kumu kemika kino:

  • ʻO ka hōʻoia ʻana i ka ʻiʻo Peptide Pūnaewele: ʻO nā paona peptide synthetic ka peptide maʻemaʻe a me ka wai paʻa a i ʻole counter-ions. Me ka ʻole o ka hoʻoholo ʻana i ka ʻike peptide net (ma o ka hoʻopaʻa ʻana i ka waikawa amino a i ʻole ka hoʻoholo nitrogen), ʻO nā helu helu kūhelu piha e lawe i nā hewa a hiki i 30%.

  • TFA-to-Acetate Counter-Ion Exchange: Ke waiho nei ka peptide synthesis solid-phase maʻamau i ke koena TFA, he mea hoʻopaʻa paʻa ion-pairing ikaika e kinai i nā hōʻailona electrospray ma nanoLC-MS. ʻO ka hana ʻana i ka hoʻololi counter-ion i ka acetate a i ʻole ka paʻakai hydrochloride e hoʻihoʻi i ka ʻike MS.

  • Hoʻolālā Kūkākūkā o ka puka aniani: ʻO ka hoʻolālā ʻana i nā panela SIL i manaʻo ʻia e pono i ka helu m/z e hōʻoia i ka hāʻule ʻole o nā kūlana koʻikoʻi i loko o ka puka aniani kaʻawale. (maʻamau ±1 m/z) o nā analytes panel ʻē aʻe a i ʻole nā ​​mea haumia ʻole i hōʻailona ʻia.

No ke kōkua: E hōʻoia mau i nā kikoʻī counter-ion a me ka ʻikepili peptide net ma mua o ka spiking ʻana i nā kūlana SIL i loko o nā laʻana immunopurified clinical.. Ka nānā ʻana i nā alakaʻi piha ma ʻO nā Peptides Synthetic rel="follow" class="link" href="https://molchanges.com/beyond-the-coa-third-party-peptide-testing-audit-guide.html”>ʻO ka hoʻāʻo ʻana ʻo Peptide a me ka hōʻoia maikaʻi e kōkua i ka hōʻoia ʻana i ka paʻa analytical batch-to-batch.


ʻO ka hoʻonui ʻana i ka hōʻoia ʻana i ka biomarker a me ka hoʻomohala ʻana i nā biologics palekana

ʻO ka hoʻohana ʻana i kahi hoʻohālike lawelawe immunopeptidomic i hoʻohui ʻia e hāʻawi i nā pono pāʻoihana a me ka ʻepekema no ka biopharma R&D nā hui:

  1. ʻO ka hōʻoia biomarker ikaika: Hiki i nā hui unuhi ke nānā i nā hōʻailona papa kikoʻī ma nā pūʻulu maʻi lōʻihi, ka hoʻokumu ʻana i nā paepae quantitative no ka hana maʻi, pane lapaʻau, a i ʻole ka hoʻihoʻi hou ʻana i ka psoriatic arthritis. Hana ʻia ʻo Peptide

  2. De-Risking TCR-Like Biologics a me Peptide-HLA Therapeutics: Hoʻolālā ʻia nā mea olaola e hoʻopaʻa i nā paʻakikī peptide-MHC kikoʻī (e.g., ʻO nā antibodies e like me TCR a i ʻole nā ​​mea hoʻopili T-cell bispecific) koi i ka hōʻoia piha o ka paʻa hōʻike ʻana. Hoʻokumu ʻia ka helu SIL i hoʻopaʻa ʻia i ka helu kope kikoʻī kikoʻī i koi ʻia no ka pono therapeutic.

  3. Ka Hoʻopalekana Paʻa ʻole a me ka nānā ʻana i ka hoʻokō kea: Ma ka helu ʻana i ka hōʻike kumu ma waena o nā ʻiʻo olakino ʻole, Hiki i nā mea hoʻomohala biopharma ke loiloi i ka hiki ke hoʻololi i ka cross-reactivity i ka hoʻomaka ʻana o ka hoʻomohala preclinical, ka pale ʻana i nā mea ʻawaʻawa autoimmune pōʻino i nā hoʻokolohua lapaʻau.


Ka hui pū ʻana me nā Paena Peptide Kūikawā no ka holomua unuhi

ʻO ka helu ʻana i ka skewed MHC Class I peptide hōʻike i ka psoriatic arthritis e koi i ka hoʻohui pono ʻana ma waena o ka peptide chemistry a me quantitative mass spectrometry.. Loaʻa pinepine ka poʻe kūʻai puke reagent maʻamau i nā mana o ka maikaʻi kūikawā—e like me Class 100 nā kaiapuni ultra-sterile synthesis, hōʻoia ʻia ka ʻupena peptide maʻiʻo, a me ka hoʻololi ʻana o TFA-to-acetate-pono no nā immunopeptidomic kiʻekiʻe.

Ma ka leveraging Nā lawelawe peptide piha mai R&D nā hoa like me MOL Changes, Loaʻa i nā mea hoʻoholo biopharma ke komo pololei i ka hoʻolālā kaʻina hana maʻamau, kiʻekiʻe-maʻemaʻe SIL maʻamau synthesis, pau 300 nā hoʻololi hana, a me ke kākoʻo hoʻomohala ʻepekema-a-ʻepekema.

Ke hōʻoia nei kāu hui i nā pahuhopu autoimmune hou, e hōʻike ana i nā immunopeptidomes maʻi, a i ʻole ke kāʻei ʻana i nā mea ola kino alakaʻi no ka hoʻihoʻi ʻana i ka cross-reactivity, ʻO kahi peptide maʻamau i hoʻohui ʻia a me SIL kaila hana maʻamau e hāʻawi i ka ʻike nui e pono ai e holomua i ka palekana, nā lāʻau lapaʻau maikaʻi loa i loko o ke keʻena.

Miao He

Miao He

ʻepekema noiʻi ma nā ʻōnaehana hoʻouna Kaʻike kumu: Hāʻawi peptide waha, lipid nanoparticle (LNP) hoʻopili ʻana, nā peptides komo i loko o ke kelepona (CPPs), a me nā hoʻopuka hoʻokuʻu mau.

Pilikino: ʻO nā luʻi nui i ka hoʻomohala ʻana i nā lāʻau peptide aia i loko o ko lākou mau hapalua ola pōkole a paʻakikī me ka hoʻokele waha, a ʻo Miao ʻO ia kekahi loea alakaʻi i ka hoʻoponopono ʻana i kēia mau pilikia. Loaʻa iā ia ka ʻike nui ma ke kahua o nā ʻōnaehana lawe peptide. Ke hoʻomau nei ʻo ia i ka hoʻomohala ʻana i nā mea hoʻonui permeation novel a me nā nanospheres e hoʻomaikaʻi nui i ka bioavailability o peptides..

ʻIke ʻia & Nā alakaʻi hoʻoponopono
Nānā ʻia e: Ka poe akamai kumuhana
Kaʻana like i kēia ʻatikala
Home Huli Whatsapp Nā lawelawe Huahana